15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 16 firms covering Axsome Therapeutics Inc, 15 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $205.00 to $316.00, a moderate spread. The average target of $266.73 sits 28% above the current $207.73. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 55% this year and 57% next, consensus EPS building from about $0.07 next quarter toward $5.03 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS16 ratings
Strong Buy
Strong Buy00%
Buy1594%
Hold16%
Sell00%
Strong Sell00%
Based on 16 analysts giving stock ratings to Axsome Therapeutics Inc.
As of Sep, 15 of 16 firms rate AXSM a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AXSM EPS & revenue forecast
EPS · NEXT QUARTER
$0.07
Range $-0.55 – $0.68 · 11 analysts · -113% YoY
Next period, 11 analysts expect Axsome Therapeutics Inc to earn $0.07 a share (range $-0.55 – $0.68), versus $-0.56 a year earlier. Full-year consensus is $-2.64, growing to $5.03 the year after.
REVENUE · NEXT QUARTER
$297.7M
Range $237.1M – $338.0M · 11 analysts · +50% YoY
Revenue is expected to reach $297.7M (range $237.1M – $338.0M), +50.0% year-over-year. Full-year consensus is $966.2M, rising to $1.6B next year.
Top analysts covering Axsome Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AXSM.
#1
Yatin Suneja
Guggenheim · Rank #21
Buy
$275.00+32.4% to target
Overall win rate
53%
+ Follow
#2
Leonid Timashev
RBC Capital · Rank #33
Buy
$297.00+43.0% to target
Overall win rate
48%
+ Follow
#3
Ami Fadia
Needham · Rank #67
Buy
$268.00+29.0% to target
Overall win rate
47%
+ Follow
#4
Joel Beatty
Baird · Rank #80
Buy
$246.00+18.4% to target
Overall win rate
48%
+ Follow
#5
David Amsellem
Piper Sandler · Rank #107
Buy
$258.00+24.2% to target
Overall win rate
50%
+ Follow
AXSM stock forecast FAQ
What is AXSM's average 12-month price target?+
The 15 analysts with a live target average $266.73 for Axsome Therapeutics Inc over the next 12 months, ranging from a $316.00 high to a $205.00 low.
Is AXSM stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 16 analyst ratings, 15 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for AXSM?+
The Street-high target is $316.00 (Mizuho), and the Street-low is $205.00 (Leerink Partners). The average of all 15 active targets is $266.73.
How many Wall Street analysts cover AXSM?+
16 analysts have an active rating on Axsome Therapeutics Inc, and 15 firms carry a live 12-month price target.
Who is the most accurate analyst covering AXSM?+
Among analysts who currently cover AXSM, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #21). Their current call is Buy with a $275.00 target.
What is Axsome Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $0.07 per share (range $-0.55 – $0.68) across 11 analysts. Full-year EPS is projected at $-2.64, rising to $5.03 the following year.
How much revenue is Axsome Therapeutics Inc expected to report next quarter?+
Consensus revenue is $297.7M (range $237.1M – $338.0M). Full-year revenue is projected at $966.2M, growing to $1.6B next year.
Have analysts been upgrading or downgrading AXSM lately?+
As of Sep, 15 of 16 firms rate AXSM a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AXSM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
BMO Capital
